ReviewOncotarget2017
Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.The Cochrane database of systematic reviews · 2021Pooled it
- Background parenchymal enhancement and breast cancer: a review of the emerging evidences about its potential use as imaging biomarker.The British journal of radiology · 2021Pooled it
- Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.JNCI cancer spectrum · 2021Pooled it
- A Randomized Controlled Trial of Soy Isoflavone Intake on Mammographic Density among Malaysian Women.Nutrients · 2023Trial
- The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study.Breast cancer research : BCR · 2018Trial
- Article
- Development and validation of the surmising model for volumetric breast density using X-ray exposure conditions in digital mammography.Medical & biological engineering & computing · 2025Article
- Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization.Breast cancer research and treatment · 2024Article
- Mammographic density in relationships with relevant contributing factors: a multicentric study from Riyadh, Saudi Arabia.Gland surgery · 2024Article
- Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor-Positive Breast Cancer.JNCI cancer spectrum · 2022Article
- Rapid Reductions in Breast Density following Tamoxifen Therapy as Evaluated by Whole-Breast Ultrasound Tomography.Journal of clinical medicine · 2022Article
- Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients.Breast cancer research and treatment · 2021Article
- Mechanical Pressure Driving Proteoglycan Expression in Mammographic Density: a Self-perpetuating Cycle?Journal of mammary gland biology and neoplasia · 2021Review
- Identification of 31 loci for mammographic density phenotypes and their associations with breast cancer risk.Nature communications · 2020Article
- Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden.Breast (Edinburgh, Scotland) · 2020Article
- Key steps for effective breast cancer prevention.Nature reviews. Cancer · 2020Review
- Breast Mammographic Density: Stromal Implications on Breast Cancer Detection and Therapy.Journal of clinical medicine · 2020Review
- Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue CulturedFrontiers in cell and developmental biology · 2020Article
- A review of the influence of mammographic density on breast cancer clinical and pathological phenotype.Breast cancer research and treatment · 2019Review
- Predicting interval and screen-detected breast cancers from mammographic density defined by different brightness thresholds.Breast cancer research : BCR · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased mammographic density (MD) has been shown beyond doubt to be a marker for increased breast cancer risk, though the underpinning pathobiology is yet to be fully elucidated. Estrogenic activity exerts a strong influence over MD, which consequently has been observed to change predictably in response to tamoxifen anti-estrogen therapy, although results for other selective estrogen receptor modulators and aromatase inhibitors are less consistent. In both primary and secondary prevention settings, tamoxifen-associated MD changes correlate with successful modulation of risk or outcome, particularly among pre-menopausal women; an observation that supports the potential use of MD change as a surrogate marker where short-term MD changes reflect longer-term anti-estrogen efficacy. Here we summarize endocrine therapy-induced MD changes and attendant outcomes and discuss both the need for outcome surrogates in such therapy, as well as make a case for MD as such a monitoring marker. We then discuss the process and steps required to validate and introduce MD into practice as a predictor or surrogate for endocrine therapy efficacy in preventive and adjuvant breast cancer treatment settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.